ARTICLE   OPEN

Check for updates

Genetic polymorphism of CYP2C19 and subcortical variability in the human adult brain

Julia C. Stingl [1,2 ✉], Catharina Scholl[2], Julia E. Bosch[3] and Roberto Viviani[3,4]

© The Author(s) 2021

Pharmacogenetic studies have shown involvement of cytochrome P450 enzymes in the metabolism of psychotropic drugs. However, expression and activity on endogenous substrates in the brain may underlie a constitutive role of these enzymes beyond drug metabolism. CYP2C19, which is expressed in the human fetal brain during neurodevelopment, shows affinity for endogenous compounds including monoaminergic neurotransmitters, steroid hormones, and endocannabinoids. In this study ($N = 608$), we looked at the genetic polymorphism of CYP2C19 and its potential associations with structural phenotypes of subcortical brain volume with structural imaging. Using two independent volume estimation techniques, we found converging evidence for a positive association between *CYP2C19* activity scores, as inferred from the genotype, and basal ganglia and hippocampal volume. This association was present only in female individuals, raising the possibility that effects on brain morphology may arise through a mechanism involving the metabolism of estrogen steroids.

INTRODUCTION

CYP2C19 is a genetically polymorphic drug-metabolizing enzyme that, due to broad substrate specificity, metabolizes different classes of drugs including several psychotropic drugs, such as antidepressants (selective serotonin-reuptake inhibitors, tricyclic antidepressants), benzodiazepines, and antiepileptics. The genetic polymorphism influences the range in CYP2C19 enzyme activity in individuals from complete loss of functionality (poor metabolizer phenotype, *CYP2C19*2/*2* carriers) to severalfold enhancement (ultrarapid metabolizers, *CYP2C19*17* carriers [1]). Beside its role in xenobiotic metabolism, CYP2C19 is also involved in biotransformation of endogenous compounds such as neurotransmitters (e.g., hydroxytryptamine), steroid hormones (estrogen, progesterone, testosterone), fatty acids (cannabidiol), and arachidonic acid [2, 3]. While not highly expressed in extrahepatic tissues of the adult, transient CYP2C19 expression in the human fetal brain may play a role during embryogenesis and neurogenesis [4].

An important approach to documenting the role of CYP2C19 on brain structure and function is to look at individual differences associated with its genetic polymorphism. In a study by Jukic et al. of the functional phenotype of the *CYP2C19*17* genotype predicting ultrarapid metabolic activity, elevated CYP2C19 expression was associated with depressive symptoms and higher tendencies to suicidal impulses in humans [5]. Furthermore, the poor metabolizer phenotype was shown in the same study to be associated with reduced volume of the hippocampus, a common finding in studies of depression [6]. In transgenic mice expressing the human *CYP2C19* gene, impairment of hippocampal serotonin and BDNF homeostasis and increased anxiety has been shown to be involved in an anxious depressive phenotype [3, 5].

The mechanism behind the possible effects of *CYP2C19* genotype on the brain, however, are not fully understood. An intriguing aspect of this issue is that CYP2C19 is not expressed or active as enzyme in the adult brain and in neuronal cells. However, CYP2C19 mRNA was detected during neurodevelopment in neuronal cells [7], a finding that has led to several hypotheses on the possible endogenous substrates of CYP2C19 involved in neurogenesis [4]. CYP2C19-mediated metabolism of cannabinoid compunds to the 6-alpha- and the 7-hydroxy-metabolites [8] may affect cannabinoid signaling in the developing brain [4, 9], as in the migration of GABA-ergic neurons to the hippocampus [10]. Also the affinity of CYP2C19 for steroid hormones (including endogenous estrogens such as estradiol [11, 12]) deserves to be brought to attention because of the large quantitative effects of sex on brain structure and the prominent role of estrogens in controlling sexual dimorphism in the fetal brain, where estradiol is also synthetized and metabolized locally [13].

In the present study, we looked at the genetic polymorphism of CYP2C19 and its potential associations with structural subcortical brain imaging phenotypes. While compatible with the findings of Jukic et al. [5], our data showed a more extensive involvement of subcortical volumes, which increased in association with higher *CYP2C19* activity scores. Our data were also suggestive of an impact of *CYP2C19* genotype on sexual dimorphism, pointing to a possible mechanism through which these effects are produced during brain development.

Methodologically, we verified the robustness of volumetric estimates of the hippocampi and other subcortical structures by employing two very different techniques: the first was the same used by Jukic et al. [5], based on segmenting subcortical volumes directly; the second was based on the amount of deformation

[1]Institute of Clinical Pharmacology, University Hospital of RWTH Aachen, Aachen, Germany. [2]Research Division, Federal Institute for Drugs and Medical Devices, Bonn, Germany. [3]Psychiatry and Psychotherapy Clinic III, University of Ulm, Ulm, Germany. [4]Institute of Psychology, University of Innsbruck, Innsbruck, Austria. ✉email: jstingl@ukaachen.de

2

J.C. Stingl et al.

required to register these structures to a common template [14, 15]. These two different approaches provided convergent assessments of the effect of *CYP2C19* genotype on subcortical volumes.

MATERIALS AND METHODS

The study protocol was approved by the local ethics committees in Ulm and Bonn and the study was registered by the German Clinical Trials Register (DRKS-ID: 00011722, BrainCYP Study).

MRI data collection and pharmacogenetic analysis

The sample used in the study consisted of $N = 608$ healthy individuals obtained by pooling data from three samples (Allegra Ulm, $N = 175$, BrainCYP Ulm, $N = 378$, BrainCYP Bonn, $N = 55$). The final sample included 342 females (average age 24.1, std. deviation 4.3).

Healthy participants were recruited primarily from the local universities and by local announcements. Exclusion criteria were neurological or medical conditions, use of medication (except hormonal contraceptives and L-thyroxin), alcohol, or drug abuse or a history of mental illness. In order to minimize the risk of ethnic stratification, Caucasian descent was ascertained by asking about the genetic background of both parents. For more detail on cohort characteristics see Table 1.

As a part of the study procedures, a 7 ml EDTA-blood sample was taken from all participants. For genotyping, genomic DNA was isolated from the biosamples using magnetic beads with the MagNA PureLC DNA Isolation Kit—Large Volume (Roche Diagnostics GmbH., Mannheim, Germany). Genotypes for *CYP2C19*, rs12248560 (C > T) (*CYP2C19*17*) and rs42442085 (G > A) (*CYP2C19*2*), were determined by real-time PCR using SimpleProbe® probes (LightSNiP assays), designed by TIB Molbiol (Berlin, Germany). To this end, 50 ng DNA were amplified using Lightcycler® FastStart DNA Master HybProbe Mix (Roche, Germany) and the respective LightSNiP Assay. The following PCR protocol was applied: 10 min at 95 °C, followed by 45 cycles for amplification: 10 s at 95 °C, 10 s at 60 °C, 15 s at 72 °C. Melting curve analysis was performed to distinguish between the different genotypes. We used a goodness-of-fit c_2 test to evaluate agreement with Hardy–Weinberg expectations. *CYP2C19* diplotypes were assigned activity scores as shown in Table 1. If no mutation for rs12248560 and rs42442085was detected, wild-type carrier status was assumed.

The first sample was collected with a Siemens Allegra 3-Tesla scanner on the premises of the Department of Psychiatry of the University of Ulm, Germany, as previously described [16]. Briefly, MPRAGE images were collected with size $256 \times 256 \times 208$ voxels, voxel size $1 \times 1 \times 1$ mm, TR/TE 3300/96, flip angle 90°, bandwidth 1220 Hz/pixel, and field of view of 240×240. The second sample was collected on the same premises from a 3-Tesla Siemens Prisma scanner, while the third sample was collected at the DZNE in Bonn, Germany with a 3-Tesla Skyra scanner using the same sequence on both sites (as previously described [17]). In brief, multi-echo MPRAGE images were collected with size $256 \times 256 \times 176$, voxel size $1 \times 1 \times 1$ mm, TR/TE 2500/1.48, 2.98, 4.48, 5.98, 7.48, flip angle 7°, bandwidth 780 Hz/pixel, and field of view of 256×256.

FIRST is a software package for the estimation the volumes of a set of subcortical structures (hippocampus, amygdala, caudate, nucleus accumbens, pallidum, putamen, thalamus, and brainstem) from T1-weighted structural images using a Bayesian approach [18]. The FIRST code is part of the FSL software package for the analysis of imaging data (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FIRST). We used the default settings in this package to estimate volumes of these structures. FIRST computes a segmentation of these subcortical structures and counts the number of voxels in each of the

segments. In the Results section, we refer to the count for all these structures as "subcortical volume", a proxy for a global volumetric effect in FIRST analyses.

Deformation-based morphometry analyses were conducted with the SPM12 package (https://www.fil.ion.ucl.ac.uk/spm/) using the DARTEL diffeomorphic registration algorithm [19] after conducting a preliminary segmentation with the default settings provided in this package. This preliminary segmentation was also used to derive cranial and brain volume measures. The DARTEL procedure was subsequently applied to maps of gray and white matter intensities from the segmentation. To obtain estimates of subcortical volumes comparable to those obtained with FIRST, we preliminarily generated masks of subcortical structures by applying FIRST to segment the mean DARTEL-registered image. Since this image is the average from the whole sample, it includes no information on volumetric individual differences. Geometric means of the Jacobians of the deformation computed with DARTEL in each voxel were then computed for each of the subcortical masks. The geometric mean of the Jacobians for the voxels in all subcortical masks gave an estimate of "subcortical volume".

Statistical analysis of volumetric data was conducted with the freely available statistical software R (version 3.5.2, The R Project for Statistical Computing, https://www.r-project.org/) on the logarithm of volume estimates (analyses on the data without taking the logarithms gave comparable results). Boxplots were drawn with the package ggplot2 by Hadley Wickham (https://github.com/tidyverse/ggplot2).

Voxel-based analyses were conducted using a permutation technique to estimate significance levels corrected for the region of interest of the hippocampus (8000 resamples [20]) after smoothing the Jacobian images outputted by DARTEL with an isotropic smoothing kernel FWHM 6 mm with the SPM12 software. Clusters were defined by the $p < 0.01$ threshold, uncorrected. In the text, k denotes the number of voxels composing the cluster. Overlays were drawn with the freely available display software MRIcron by Chris Rorden (http://www.mccauslandcenter.sc.edu/crnl/mricro).

RESULTS

Jukic et al. [5] had shown in two independent samples that CYP2C19 poor metabolizers (homozygous carriers of the *2 allele) had a larger hippocampus than carriers of other genotypes after adjusting for subcortical volumetric effects and the confounds of sex, age, and scan hardware versions (for the sake of comparability, the term 'subcortical volumes' here refers to the volumes for which the package used by Jukic et al. [5] provides a volumetric estimate, as detailed in the Methods). In our data and using the same methodological approach to assess volumes, the hippocampal volume of poor CYP2C19 metabolizers was 2.5% larger than in the rest of the sample after adjusting for total subcortical volume, age, sex, and scanning site, but this effect failed to reach significance ($t_{601} = 1.04$, $p = 0.15$, one-tailed, Fig. 1). As detailed in the Methods, to verify robustness of volumetric

Fig. 1 Boxplots of estimated hippocampal volumes, after adjustment for subcortical volume, sex, age, and site. The position of the observations on the x-axis was jittered to improve visualization.

Table 1. Genetic composition of the sample.

Genotype	Activity score	N	N females	N males
*2/*2 (PM)	0	10	7	3
*2/*1	1	113	59	54
*2/*17	1	22	15	7
*1/*1 (WT)	2	263	156	107
*1/*17	3	167	89	78
*17/*17 (UM)	4	33	16	17

PM poor metabolizer, *WT* wild type, *UM* ultrarapid metabolizer.

SPRINGER NATURE

Translational Psychiatry (2021)11:467

estimates we conducted parallel analyses using a deformation-based method. In the deformation-based analysis of the same model, the effect of poor metabolizer status on hippocampal volume was significant ($t_{601} = 1.71$, $p = 0.044$, one-tailed). However, we noticed that the poor metabolizer phenotype was also weakly associated with subcortical volume as a whole ($t_{602} = -1.46$, $p = 0.14$), one of the adjustment terms in the model.

When considering subcortical volume in its own right, our data gave a different picture of the relationship between *CYP2C19* genotype and brain structure. This association was significant when tested on the activity score as predicted by the genotype (i.e., when accounting for the effect of all genotypes: $t_{602} = 2.24$, $p = 0.025$; similar results were obtained with deformation-based technique, $t_{602} = 1.82$, $p = 0.07$). A unit difference in the activity score corresponded to an increment of about 0.8% in subcortical volume (giving a difference of 3.2% for the score range; Fig. 2).

This is of potential relevance because, together with the strong association between total subcortical volume and hippocampal volume (more than 90% in our data), it may affect estimates of the association between this latter and the ultrarapid metabolizer phenotype when adjusting for subcortical volume. Indeed, in a model without adjustment for subcortical volume, hippocampal volume was in our data positively associated with the *CYP2C19* activity score (1% volume increment per activity score unit, $t_{602} = 2.28$, $p = 0.023$).

As one might surmise by these findings, in the absence of adjustment for subcortical volume the positive association between *CYP2C19* activity scores and volume was present in most subcortical structures (see Table 2). Because the precision with which the volumes of anatomical structures are estimated varies, significance values do not necessarily correspond to the estimated size of effects.

Fig. 2 Global subcortical volumes with respect of *CYP2C19* activity scores, adjusted for sex, age, and site. In contrast to Fig. 1, voumes increase with activity scores.

The effects of CYP2C19 polymorphism on cranial or brain volume were less marked than those for subcortical volumes (cranial volume, 0.5% increase per score unit, $t_{602} = 1.57$, $p = 0.12$; brain volume, 0.3%, $t_{602} = 1.06$, n.s.), suggesting some degree of specificity of the effect on subcortical volumes. After adjusting for subcortical volume, there was no residual effect on the effect on cranial and brain volumes, which again suggests that the small effects on cranial and brain volume may be driven by the increase in the subcortical compartment. In line with this interpretation of the data, the effects *CYP2C19* activity scores on the subcortical volume persisted when adjusting for brain (0.5% per unit score increase, $t_{601} = 2.23$, $p = 0.02$) or cranial volume (0.4%, $t_{601} = 1.60$, $p = 0.06$, one-tailed). In summary, the effects of *CYP2C19* activity scores on subcortical volumes appeared to be specific and decoupled from effects (or lack thereof) on brain or cranial size.

Sex differences

Because of the involvement of CYP2C19 in the biotransformation of steroid hormones and estrogens, we were interested in looking at whether the effect of the genetic polymorphism was sensitive to sex differences. In our data, the association with subcortical volume was stronger in females ($t_{337} = 2.74$, $p = 0.003$), where one unit score corresponded to about 1.2% relative increment, than in males (0.2% increase per score unit, $t_{261} = 0.41$, n.s.), as shown in the interaction ($t_{601} = 1.51$, $p = 0.065$, one-tailed).

As in the data for the whole cohort, this interaction could not be attributed to a generic effect on cranial size reflected in the data for the subcortical volume. After adjusting for cranial volume, the interaction between subcortical volume, sex, and *CYP2C19* activity score persisted ($t_{600} = 1.69$, $p = 0.046$; Fig. 3A). The deformation-based analysis gave very similar results ($t_{600} = 1.68$, $p = 0.046$). Visualization of the sex differences using the deformation-based data revealed a diffuse subcortical involvement in females, with more marked effects in the anterior pallidum and the thalamus (Fig. 3B).

DISCUSSION

In this study of $N = 608$ healthy individuals we detected a significant association between CYP2C19 activity predicted by genotype and subcortical brain volume. This finding is consistent with previous reports on the existence of effects of *CYP2C19* polymorphism and structural neuroimaging data [5, 21]. However, our analysis disclosed a more complex set of effects than previously surmised, for which three possible interpretations may be given.

First, while of only borderline significance, our data essentially replicated the finding reported by Jukic et al. [5] of larger hippocampal size in poor CYP2C19 metabolizers after adjusting

Table 2. Effect of *CYP2C19* activity score on subcortical volumes.

Region	FIRST			Deformation based		
	% change	*t*	*p*	% change	*t*	*p*
Caudate	0.8 ± 0.5	1.72	0.086	0.8 ± 0.5	1.90	0.058
Nucl. acc.	1.5 ± 1.1	1.38	0.166	0.1 ± 0.4	0.24	n.s.
Pallidum	0.9 ± 0.4	2.18	0.030	0.6 ± 0.4	1.84	0.066
Putamen	0.5 ± 0.4	1.18	0.239	0.4 ± 0.4	1.08	0.282
Thalamus	0.6 ± 0.4	1.57	0.117	0.7 ± 0.3	1.95	0.052
Hippocampus	1.1 ± 0.5	2.28	0.023	0.7 ± 0.3	2.29	0.022
Amygdala	1.1 ± 0.6	1.80	0.073	0.3 ± 0.4	0.90	n.s.
Brainstem	0.9 ± 0.5	1.84	0.066	0.5 ± 0.3	1.41	0.160

df = 602.
% change percent change and standard error of estimate.

A

B

Fig. 3 Sex differences in CYP2C19 activity effects on subcortical brain volume and in deformation-based analysis. A Effects of *CYP2C19* activity on subcortical brain volume in males and females. The regression line for males runs essentially flat (in red), whereas the line for females shows an increase in volume with increasing activity scores (in light blue), so that sexual dimorphism is small or nonexistent in ultrarapid metabolizers (score = 4). Data adjusted for age, site, and cranial volume. **B** Statistical maps of *t* values obtained from the voxelwise regression of deformation values on *CYP2C19* activity scores in females (in blue-green) and males (red-yellow), thresholded for display purposes at $p < 0.05$, uncorrected, overlaid on a template brain. Positive *t* values indicate larger structures. The ovals outline the effects on the basal ganglia.

for subcortical volume, and showed this effect to be robust relative to the specific technique used to assess hippocampal volume. This finding has been interpreted in support for an affective vulnerability phenotype of CYP2C19 poor metabolizers [3]. In our data, however, subcortical volume was itself associated with *CYP2C19* activity scores; without adjustment, the association was in the other direction. This suggests that adjustment for subcortical volume may affect the relationship between individual structures and CYP2C19 polymorphism, rather than simply adjusting for a neutral baseline, thus accounting for the reversal of the sign of the association with and without adjustment.

A second interpretive line arises from noting that in our sample the CYP2C19 polymorphism effect on subcortical volume was more pronounced in women. The evidence for the interaction with sex was only suggestive in our data. However, it provides a potential mechanism for the effect of this polymorphism on brain size, because sex alone has a large effect on brain size [22]. This effect is thought to be mediated by the neurotrophic activity of sex hormones during gestation and adolescence [23, 24]. A distinction between sexual dimorphism in brain structure is usually made between a global effect, with ~10% larger brain size in males, and relative effects that affect most markedly the medial temporal lobe and the basal ganglia [24, 25]. In our sample, the interaction between *CYP2C19* genotype and sex involved subcortical structures, while there was no evidence for a global effect on brain volume.

Several findings support the role of sex hormones in the effects of CYP2C19 polymorphism on brain structure. The role of CYP2C19 in estradiol biotransformation is important for endogenous as well as exogenous estrogens such as oral contraceptives. 17-beta-hydroxydehydrogenation and 16-alpha-hydroxylation of estradiol and similar compound is mediated by CYP2C19 [11, 12]. Therefore, lower activity of CYP2C19 may cause higher estrogen levels, and vice versa. Consistently with the notion that estrogen exposure is

lower in carriers of the high-activity *CYP2C19*17* allele, ultrarapid metabolizers have been shown to present lower incidence of breast cancer, and lower recurrences of hormonal sensitive breast cancer after treatment with tamoxifen [26, 27]. Furthermore, the expression of CYP2C19 is partially regulated through a mechanism elucidated recently. The estrogen receptor alpha specifically binds to the promotor of the *CYP2C19* gene and leads to a decrease in enzyme activity through transcriptional downregulation of *CYP2C19* gene expression, rather than direct estrogen-mediated steroid–protein interaction [28]. Interestingly, the activity of the *CYP2C19*17* allele, which leads to ultrarapid metabolizer phenotypes by an increased transcription rate, is not affected by estrogen receptor alpha-mediated CYP2C19 inhibition as shown in vivo with oral contraceptives [29]. In normal and intermediate metabolizers, estrogen receptor-mediated CYP2C19 inhibition may lead to lower estrogen degradation, shifting activity towards the levels of poor metabolizers. In contrast, in carriers of the *CYP2C19*17* allele, the ultrarapid metabolizer phenotype remains unaffected by estrogen receptor alpha-mediated CYP2C19 inhibition. Thus, the interaction with estrogen-mediated inhibition of the enzyme and estradiol biotransformation as a substrate of CYP2C19 may amplify the phenotypic expression of CYP2C19 genotypes in women. Hence, the association of subcortical volume with *CYP2C19* activity scores in females may derive from overall estrogen exposure that is higher in poor metabolizers leading to an enhanced female dimorphism brain structural phenotype. In contrast, female *CYP2C19*17/*17* carriers were like males with regard to the effects of this genotype on subcortical volume and hippocampus size.

Finally, the observed association between *CYP2C19* genotype and subcortical volume affected specifically the basal ganglia. The function of these subcortical structures is predominantly dopaminergic with effects on reward or overall emotional processing. This hypothesis is consistent with the previously reported higher concentration of dopamine in the brain of transgenic mice expressing human CYP2C19 [21]. Several studies have documented sexual dimorphism in humans in basal ganglia dopamine function [30–32]; hence, this finding is not incompatible with the two previous hypotheses.

On a methodological note, we could show that volumetric assessment through MRI led to comparable results across studies irrespective of methodology. The apparent discrepancies in assessing relative effects of individual brain structures were due to issues intrinsic to the rationale for adjusting for global volumetric effects and not to methodology.

REFERENCES

1. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, et al. A common novel *CYP2C19* gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump nhibitors and antidepressants. Clin Pharmacol Ther. 2006;79:103–13.
2. Stingl JC, Brockmöller J, Viviani R. Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Mol Psychiatry. 2013;18:273–87.
3. Persson A, Sim SC, Virding S, Onishchenko N, Schulte G, Ingelman-Sundberg M. Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene. Mol Psychiatry. 2013;19:733–714.
4. Ingelman-Sundberg M, Persson A, Jukic MM. Polymorphic expression of CYP2C19 and CYP2D6 in the developing and adult human brain causing variability in cognition, risk for depression and suicide: the search for the endogenous substrates. Pharmacogenomics. 2014;15:1841–4.
5. Jukić MM, Opel N, Ström J, Carrillo-Roa T, Miksys S, Novalen M, et al. Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment. Mol Psychiatry. 2016;22:1155–63.
6. Sheline YI. Depression and the hippocampus: cause or effect? Biol Psychiatry. 2011;70:308–9.
7. Persson A, Ingelman-Sundberg M. Pharmacogenomics of cytochrome P450 dependent metabolism of endogenous compounds: implications for behavior,

psychopathology and treatment. J Pharmacogenom Pharmacoproteomics. 2014;5:2.

8. Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci. 2011;89:165–70.

9. Berghuis P, Rajnicek AM, Morozov YM, Ross RA, Mulder J, Urbán GM, et al. Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science. 2007;316:1212.1216–6.

10. Berghuis P, Dobszay MB, Wang X, Spano S, Ledda F, Sousa KM, et al. Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proc Natl Acad Sci USA. 2005;102:19115–20.

11. Cheng ZN, Shu Y, Liu ZQ, Wang LS, Ou-Yang DS, Zhou HH. Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001;22:148–54.

12. Cribb AE, Knight MJ, Dryer D, Guernsey J, Hender K, Tesch M, et al. Role of polymorphic human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol Prev Biomark. 2006;15:551–8.

13. McCarthy MM. Estradiol and the developing brain. Physiol Rev. 2008;88:91–134.

14. Ashburner J, Hutton C, Frackowiak R, Johnsrude I, Price C, Friston K. Identifying global anatomic differences: deformation-based morphometry. Hum Brain Mapp. 1998;6:348–57.

15. Gaser C, Volz H-P, Keibel S, Riehemann S, Sauer H. Detecting structural changes in whole brain based on nonlinear deformations—application to schizophrenia research. NeuroImage. 1999;10:107–13.

16. Viviani R, Beschoner P, Ehrhard K, Schmitz B, Thöne J. Non-normality and transformations of random fields, with an application to voxel-based morphometry. NeuroImage. 2007;35:121–30.

17. Viviani R, Stöcker T, Stingl JC. Multimodal FLAIR/MPRAGE segmentation of cerebral cortex and cortical myelin. NeuroImage. 2017;152:130–41.

18. Patenaude B, Smith SM, Kennedy D, Jenkinson M. A Bayesian model of shape and appearance for subcortical brain. NeuroImage. 2011;56:907–22.

19. Ashburner J. A fast diffeomorphic image registration algorithm. NeuroImage. 2007;38:95–113.

20. Holmes AP, Blair RC, Watson JDG, Ford I. Nonparametric analysis of statistic images from functional mapping experiments. J Cereb Blood Flow Metab. 1996;16:7–22.

21. Stingl JC, et al. Effects of CYP2C19 polymorphism on voxel-based morphometry. in *Human Brain Mapping Annual Meeting* (Geneva, 2016).

22. Gur RC, Turetsky BI, Matsui M, Yan M, Bilker W, Hughett P, et al. Sex differences in brain gray and white matter in healthy young adults: Correlations with cognitive performance. J Neurosci. 1999;19:4065–72.

23. Goldstein JM, Seidman LJ, Horton NJ, Makris N, Kennedy DN, Caviness VS Jr, et al. Normal sexual dimorphism of the adult human brain assessed by in vivo magnetic resonance imaging. Cereb Cortex. 2001;11:490–7.

24. Lenroot RK, Giedd JN. Sex differences in the adolescent brain. Brain Cogn. 2010;72:46–55.

25. Rijpkema M, Everaerd D, van der Pol C, Franke B, Tendolkar I, Fernández G. Normal sexual dimorphism in the human basal ganglia. Hum Brain Mapp. 2012;33:1246–52.

26. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007;33:5187–93.

27. Justenhoven C, Hamann U, Pierl CB, Baisch C, Harth V, Rabstein S, et al. *CYP2C19*17* is associated with decreased breast cancer risk. Epidemiology. 2009;115:391–6.

28. Mwinyi J, Cavaco I, Pedersen RS, Persson A, Burkhardt S, Mkrtchian S, et al. Regulation of CYP2C19 expression by estrogen receptor α: Implications for estrogen-dependent inhibition of drug metabolism. Mol Pharmacol. 2010;78:886–94.

29. Pedersen RS, Noehr-Jensen L, Brosen K. Inhibitory effects of oral contraceptives on CYP2C19 activity is not significant in carriers of the *CYP2C19*17* allele. Clin Exp Pharmacol Physiol. 2013;40:683–8.

30. Pohjalainen T, Rinne JO, Nagren K, Syvälahti E, Hietala J. Sex differences I the striatal dopamie D_2 receptor binding characteristics in vivo. Am J Psychiatry. 1998;155:768–73.

31. Laakso A, Vilkman H, Bergman J, Haaparanta M, Solin O, Syvälahti E, et al. Sex differences in sriatal presynaptic dopamine synthesis capacity in healthy subjects. Biol Psychiatry. 2002;52:759–63.

32. Munro CA, McCaul ME, Wong DF, Oswald LM, Zhou Y, Brasic J, et al. Sex differences in striatal dompamine release in healthy adults. Biol Psychiatry. 2009;59:966–74.

AUTHOR CONTRIBUTIONS

JS and RV designed the research. CS was responsible for the genetic analyses, biosampling, and data analysis. RV and JB analyzed and collected the imaging data, RV and JS wrote the manuscript. All authors read the manuscript.

FUNDING INFORMATION

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Julia C. Stingl.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.